Svensson CK, et al. - Considering a previous randomized trial showed a positive effect of 16 weeks of glucagon-like peptide-1 receptor agonist liraglutide treatment vs placebo in terms of significantly reducing glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine, researchers examined if the beneficial effects of this 16-week intervention continued beyond the intervention period. For this purpose, changes in body weight, fasting glucose, glycated hemoglobin, C-peptide and lipids were investigated 1 year after completion of the intervention and a comparison of 1-year follow-up levels to end of treatment (week 16) and baseline (week 0) levels was performed. One year after the intervention was completed, a partial sustaining of the body weight reduction achieved during 16 weeks of liraglutide treatment was noted. However, the other metabolic parameters returned to baseline levels.